Nabiximols

Biopharmaceutical company GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Tuesday that its revenue for the third quarter hit $137.1 million, up by 51% year-over-year. For the first nine months of this fiscal year, total revenue amounted to $378.6 million versus $202.3 million for the...

GW Pharmaceuticals plc (NASDAQ: GWPH) said Monday it will obtain exclusive rights for the commercialization of Sativex in the U.K. from Bayer AG (OTC: BAYRY). Sativex is an oromucosal spray with the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) in a 1-to-1 ratio....